蛋白激酶BRSK2在胰腺导管腺癌中的表达及意义

目的 探讨蛋白激酶脑选择性激酶2(BRSK2)在胰腺导管腺癌中的表达情况及其与肿瘤的生物学行为之间的关系和对患者预后的影响.方法 79例胰腺导管腺癌组织标本取自复旦大学中山医院2005年至2007年获得手术切除且具有完整临床及随访资料的病例,利用免疫组织化学SABC方法对病理石蜡切片进行染色,对染色结果进行半定量分析,以3例正常胰腺组织中的染色情况作对照,观察BRSK2在胰腺癌及癌周正常组织中的表达情况.对所选病例按照肿瘤分化程度、TNM分期、有无血管、神经及淋巴结转移等进行分类,观察免疫组化结果与肿瘤生物学行为之间有无关联,并进一步分析BRSK2在肿瘤组织中的表达情况及对患者预后的影响.结果 BRSK2在正常胰腺组织中主要表达于胰岛以及小的导管如闰管、小叶内导管、小叶间导管等,但表达强度较弱;BRSK2在导管腺癌的癌周组织中表达亦较弱;BRSK2在79例胰腺导管腺癌中77例表达较强(++38例,+++39例);其表达与肿瘤有无淋巴结转移及远处转移、肿瘤的分期以及有无胰周神经浸润有关,在伴有淋巴结或远处转移、TNM晚期以及伴有胰周神经浸润的肿瘤中表达较强;而与肿瘤大小、分化及有无血管侵犯无关;BRSK2表达较强的肿瘤患者的预期生存期、中位生存期、1年和2年生存率均显著低于表达较弱的患者.结论 BRSK2在胰腺导管腺癌中表达上调,其表达强度与导管腺癌生物学行为之间存在显著相关,BRSK2在导管腺癌中的表达可能与患者的预后有关.

Clinical implication of BRSK2 expression in pancreatic ductal adenocarcinoma

Objective To investigate the expression of BRSK2(brain selective kinase 2)in pancreatic ductal adenocarcinoma and to understand its clinical implication.Methods Resected tumor specimens of 79 pancreatic ductal adenocarcinoma were collected and paraffin-embedded for prepare.0.5μm sections.Immunohistochemical staining was employed to examine the expression pattern of BRSK2 translated protein.Semi-quantitative analysis was used to evaluate the intensity and content of protein expression in tumor tissues.The expression outcome was compared in peri-tumorous tissues and normal pancreatic tissues.Meanwhile,tumor samples were grouped according to their differentiation,TNM stage,with or without vascular or neural invasion.Then the possible relationship was explored between clinical,pathological and survival data and the expression profile of BRSK2 in tumor tissues.Results BRSK2's expression was weak in normal pancreatic tissues,including islets and minor ducts such as intercalated ducts,intralobular ducts and interlobular ducts.BRSK2's expression was also weak in peri-tumorous tissues.BRSK2's expression was strong in pancreatic ductal adenocarcinomns.It had a close relationship with lymphatic metastasis,distant metastasis,TNM staging as well as peri-pancreatic neural invasion.Tumors with lymphatic metastasis,distant metastasis and peri-pancreatic neural invasion or at later stages showed a higher expression of BRSK2 than those without or those at early stages.However the expression had no correlmion with tumor size,differentiation and vascular invasion.The expression of BBSK2 in pancreatic ductal adenocarcinonms was correlated with the prognosis of patients.Those with a higher expression pattern showed a shorter survival period.Conclusion BRSK2 is up-regulated in pancreatic ductal adenocarcinoma.And its expression is correlated with tumor biological behaviors and patient prognosis.